Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinoma

1 Mar 2025

Abstract excerpt

Objective Telomerase reverse transcriptase (TERT) gene promoter mutation (TPM) is a key non-coding somatic alteration in urothelial carcinoma (UC) that plays a critical role in telomerase activation. Despite its importance, the prognostic value of TPM has shown mixed results in previous studies. Methods and analysis This study included 155 UC patients from two local clinical centres and 1652 patients from four...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Ferroptosis and cancer prognosis
Share to Telomeres, Telomerase, and Senescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40099003
DOI: 10.1136/bmjonc-2024-000586

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinomaPMID 40099003Read ↗

A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.Semantic proximity Read ↗

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.Semantic proximity Read ↗

TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.Semantic proximity Read ↗

Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.Semantic proximity Read ↗

Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.Semantic proximity Read ↗

High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.Semantic proximity Read ↗

Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancerSemantic proximity Read ↗

Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.Semantic proximity Read ↗

Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.Semantic proximity Read ↗

TERT promoter mutations and methylation for telomerase activation in urothelial carcinomas: New mechanistic insights and clinical significance.Semantic proximity Read ↗

Effect of co-occurring mutations in TP53 gene and TERT promoter on the survival of bladder cancer patients.Semantic proximity Read ↗

Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.